Michigan State University researchers use AI and nanomedicine to identify blood-based biomarkers for prostate cancer and atherosclerosis.
Key Details
- 1Researchers from MSU, Augusta University, Karolinska Institute, and Stanford developed a new diagnostic platform.
- 2The method combines nanomedicine, AI, and causal analysis to identify rare plasma protein biomarkers.
- 3Initial targets were metastatic prostate cancer and atherosclerosis (clogged arteries).
- 4Published in the Chemical Engineering Journal on April 1, 2025.
- 5Funding from the American Heart Association, DoD Prostate Cancer Research, NIH, and NSF.
Why It Matters
Integrating radiology expertise with AI-driven biomarker discovery could transform early detection and precision medicine, providing radiologists with novel tools for non-invasive disease diagnosis. These advances support the radiology-AI community's efforts to enhance diagnostic accuracy and patient stratification.
Source
EurekAlert
Related News
•EurekAlert
Chinese Researchers Unveil Photonic Chip for Ultra-Fast Image Processing
A new photonic chip achieves image processing at 25 million frames per second with high energy efficiency, promising major advances in real-time imaging and AI applications.
•EurekAlert
AI Model Predicts Growth Spurts from Pediatric Neck X-rays for Orthodontics
Korean researchers developed an AI system (ARNet-v2) that predicts children's growth spurts from neck X-rays to enhance orthodontic treatment planning.
•EurekAlert
Dana-Farber Showcases AI and Clinical Trial Advances at ESMO 2025
Dana-Farber researchers present major cancer clinical trial results, including AI-driven data analysis, at ESMO Congress 2025.